1GLP-1 GLP-1 GLP-1 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 GLP-1 derived peptide or GLP-1 degradation inhibitor

The present invention relates to: a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia comprising a glucagon-like peptide-1 (GLP-1), a GLP-1 derived peptide, or a GLP-1 decomposition inhibitor; and a method for treating muscle atrophy or sarcopenia by using the pharma...

Full description

Saved in:
Bibliographic Details
Main Authors JEON HEE SOOK, LEE JONG HAN, SUNG MIN AHN, HONG YEON HEE
Format Patent
LanguageEnglish
Korean
Published 01.11.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to: a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia comprising a glucagon-like peptide-1 (GLP-1), a GLP-1 derived peptide, or a GLP-1 decomposition inhibitor; and a method for treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition provided by the present invention is administered to a subject having sarcopenia or muscle atrophy, a body weight, a weight of skeletal muscle, a grip power, and expression levels of genes involved in muscle formation reduced due to sarcopenia or muscle atrophy can be restored to a normal state. Therefore, the composition can be widely used for developing effective therapeutic agents for sarcopenia or muscle atrophy. 본 발명은 글루카곤 유사 펩타이드-1(GLP-1), GLP-1 유래 펩타이드, 또는 GLP-1 분해 억제제를 포함하는 근위축증 또는 근감소증 예방 또는 치료용 약학 조성물 및 상기 약학 조성물을 사용하여 근위축증 또는 근감소증을 치료하는 방법에 관한 것이다. 본 발명에서 제공하는 약학 조성물을 근감소증 또는 근위축증이 발병된 개체에 투여하면, 근감소증 또는 근위축증으로 인하여 감소된 체중, 골격근의 중량, 악력 및 근육 생성에 관여하는 유전자의 발현수준을 정상상태로 회복시킬 수 있으므로, 효과적인 근감소증 또는 근위축증의 치료제 개발에 널리 활용될 수 있을 것이다.
Bibliography:Application Number: KR20190133776